MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Triciribine

CAS No. : 35943-35-2

MCE 站：Triciribine

产品活性：Triciribine 是一种 DNA 合成 (DNA synthesis) 抑制剂，也抑制 Akt 和 HIV-1/2，IC₅₀ 分别为 130 nM 和 0.02-0.46 μM。

研究领域：Cell Cycle/DNA Damage  |  PI3K/Akt/mTOR  |  Anti-infection

作用靶点：DNA/RNA Synthesis  |  Akt  |  HIV

In Vitro: The nucleoside analog Triciribine (TCN) is a purine analog which is initially shown to inhibit DNA synthesis. Triciribine selectively inhibits the phosphorylation and activation of all three Akt isoforms. At a concentration of 10 μM Triciribine Akt phosphorylation is inhibited at both Thr308 and Ser473. Triciribine effectively inhibits the phosphorylation and consequently the catalytic activity of Akt in PC-3 cells. The Akt inhibitor Triciribine (TCN) does not effectively inhibit the human cell line U87MG but inhibits other astrocytoma cell lines in a grade-dependent manner. The WHO II K1861-10 line is incompletely inhibited (69% maximum inhibition) with a GI₅₀ value of 1.7 ?M for Triciribine. Triciribine exhibits maximum growth inhibition around 1-10 ?M and inhibits phosphorylation of Akt, as well as downstream p70S6K, to basal levels at 100 ?M (IC₅₀=130 nM) in KR158 cells. Triciribine (TCN) is a novel tricyclic compound with known antitumor activity. Using a syncytial plaque assay, Triciribine is active against HIV-1 at 0.01-0.02 μM. Using a microtiter XTT assay, Triciribine is active against a panel of HIV-1 and HIV-2 strains at IC₅₀ values ranging from 0.02 to 0.46 μM.

In Vivo: Triciribine (TCBN) treatment, administered for 7 days after 14 days of hypoxia until 21 days of hypoxia is reached, reversed the vascular thickening as shown by immunohistochemistry and Western analyses. On the other hand, Rapamycin treatment did not prevent hypoxia-induced pulmonary alveolar haemorrhage and congestion. Triciribine partially inhibits progressive pruning of the vasculature.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Doxorubicin hydrochloride  |  Cycloheximide  |  Chloroquine  |  5-Fluorouracil  |  Oxaliplatin  |  Gemcitabine  |  Actinomycin D  |  Mitomycin C  |  Bleomycin sulfate  |  Carboplatin  |  Cytarabine  |  Favipiravir  |  Valproic acid  |  Methotrexate  |  Streptozocin  |  Anisomycin  |  (-)-Epigallocatechin Gallate  |  Shikonin  |  Fludarabine  |  Thymidine  |  Ivermectin  |  Honokiol  |  Ebselen  |  Kaempferol  |  Epirubicin hydrochloride  |  Flavopiridol  |  Daunorubicin hydrochloride  |  Maraviroc

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。